Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 106
- Registration Number
- NCT00656617
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT00620321
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
- Conditions
- Interventions
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT00542971
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
- Conditions
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00534469
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 111
- Registration Number
- NCT00528398
- Locations
- 🇺🇸
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00528450
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT00505700
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel/ Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
- Conditions
- First Posted Date
- 2007-06-18
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 200
- Registration Number
- NCT00487448
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
Phase III Trial in Acute Promyelocytic Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2022-10-12
- Target Recruit Count
- 276
- Registration Number
- NCT00482833
- Locations
- 🇦🇹
Universitätsklinik Innsbruck Hämatologie Onkologie, Innsbruck, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria
🇦🇹Universitätsklinik für Innere Medizin III Salzburg, Salzburg, Austria
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 14
- Registration Number
- NCT00469859
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.